Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated LR-MDS Patients
rigel pharmaceuticals在第66屆美國血液學會年會上重點介紹了正在進行的10億階段研究的初步數據，該研究評估了R289在LR-MDS中的應用；R289整體耐受性良好，並在重度預處理的老年LR-MDS患者中顯示出初步臨床活性的跡象。
- R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients
- RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD
- R289整體耐受性良好，並在重度預處理的老年LR-MDS患者中顯示出初步臨床活性的跡象。
- 在接受R289劑量≥500毫克QD的40%的可評估TD患者中發生了RBC-TI/HI-E反應。
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.
加利福尼亞州南舊金山，2024年12月9日 /芝加哥商業新聞/ -- rigel pharmaceuticals, Inc. (納斯達克:RIGL)是一家專注於血液疾病和癌症的商業階段生物技術公司，今天宣佈了其正在進行的10億階段研究的初步數據，該研究評估了R2891——一種R835的口服前藥，R835是一種有效且選擇性強的雙重抑制劑，對IRAK1和IRAK4在複發性或難治性(LR)低風險骨髓增生異常綜合徵患者中的應用。數據由Guillermo Garcia-Manero博士（海報編號：4595）在第66屆美國血液學會(ASH)年會暨博覽會期間於加利福尼亞州聖地亞哥和線上展示，會議時間爲12月7日至10日。
